Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer
Abstract Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-38750-9 |
| _version_ | 1827933277072130048 |
|---|---|
| author | Isabel Tundidor Marta Seijo-Vila Sandra Blasco-Benito María Rubert-Hernández Sandra Adámez Clara Andradas Sara Manzano Isabel Álvarez-López Cristina Sarasqueta María Villa-Morales Carmen González-Lois Esther Ramírez-Medina Belén Almoguera Antonio J. Sánchez-López Laura Bindila Sigrid Hamann Norbert Arnold Christoph Röcken Ignacio Heras-Murillo David Sancho Gema Moreno-Bueno María M. Caffarel Manuel Guzmán Cristina Sánchez Eduardo Pérez-Gómez |
| author_facet | Isabel Tundidor Marta Seijo-Vila Sandra Blasco-Benito María Rubert-Hernández Sandra Adámez Clara Andradas Sara Manzano Isabel Álvarez-López Cristina Sarasqueta María Villa-Morales Carmen González-Lois Esther Ramírez-Medina Belén Almoguera Antonio J. Sánchez-López Laura Bindila Sigrid Hamann Norbert Arnold Christoph Röcken Ignacio Heras-Murillo David Sancho Gema Moreno-Bueno María M. Caffarel Manuel Guzmán Cristina Sánchez Eduardo Pérez-Gómez |
| author_sort | Isabel Tundidor |
| collection | DOAJ |
| description | Abstract Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease. |
| first_indexed | 2024-03-13T07:22:31Z |
| format | Article |
| id | doaj.art-ab9e0b407ed94740a55b818db99ef737 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-03-13T07:22:31Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-ab9e0b407ed94740a55b818db99ef7372023-06-04T11:33:20ZengNature PortfolioNature Communications2041-17232023-05-0114111510.1038/s41467-023-38750-9Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancerIsabel Tundidor0Marta Seijo-Vila1Sandra Blasco-Benito2María Rubert-Hernández3Sandra Adámez4Clara Andradas5Sara Manzano6Isabel Álvarez-López7Cristina Sarasqueta8María Villa-Morales9Carmen González-Lois10Esther Ramírez-Medina11Belén Almoguera12Antonio J. Sánchez-López13Laura Bindila14Sigrid Hamann15Norbert Arnold16Christoph Röcken17Ignacio Heras-Murillo18David Sancho19Gema Moreno-Bueno20María M. Caffarel21Manuel Guzmán22Cristina Sánchez23Eduardo Pérez-Gómez24Department of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityBrain Tumor Research Program, Telethon Kids InstituteBreast Cancer Group, Oncology Area, Biodonostia Health Research InstituteBreast Cancer Group, Oncology Area, Biodonostia Health Research InstituteUnit of Information and Healthcare Results, OSI Donostialdea, Biodonostia Health Research InstituteCentro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM)Department of Pathology, Hospital Universitario Puerta de Hierro, MajadahondaDepartment of Obstetrics & Gynecology, Hospital Universitario Puerta de Hierro, MajadahondaDepartment of Obstetrics & Gynecology, Hospital Universitario Puerta de Hierro, MajadahondaBiobank Hospital Universitario Puerta de Hierro MajadahondaClinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical CenterDepartment of Gynecology and Obstetrics, University Hospital Schleswig-HolsteinDepartment of Gynecology and Obstetrics, University Hospital Schleswig-HolsteinInstitute of Pathology, University Hospital Schleswig-HolsteinImmunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC)Immunobiology Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC)MD Anderson International Foundation; Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM); Department of Biochemistry, Autonomous University of Madrid; Instituto de Investigación Hospital Universitario La Paz (IdiPaz); Centro de Investigación Biomédica en Red de Cáncer (CIBERONC)Breast Cancer Group, Oncology Area, Biodonostia Health Research InstituteDepartment of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityDepartment of Biochemistry and Molecular Biology, Complutense UniversityAbstract Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.https://doi.org/10.1038/s41467-023-38750-9 |
| spellingShingle | Isabel Tundidor Marta Seijo-Vila Sandra Blasco-Benito María Rubert-Hernández Sandra Adámez Clara Andradas Sara Manzano Isabel Álvarez-López Cristina Sarasqueta María Villa-Morales Carmen González-Lois Esther Ramírez-Medina Belén Almoguera Antonio J. Sánchez-López Laura Bindila Sigrid Hamann Norbert Arnold Christoph Röcken Ignacio Heras-Murillo David Sancho Gema Moreno-Bueno María M. Caffarel Manuel Guzmán Cristina Sánchez Eduardo Pérez-Gómez Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer Nature Communications |
| title | Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| title_full | Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| title_fullStr | Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| title_full_unstemmed | Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| title_short | Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| title_sort | identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer |
| url | https://doi.org/10.1038/s41467-023-38750-9 |
| work_keys_str_mv | AT isabeltundidor identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT martaseijovila identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT sandrablascobenito identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT mariaruberthernandez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT sandraadamez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT claraandradas identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT saramanzano identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT isabelalvarezlopez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT cristinasarasqueta identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT mariavillamorales identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT carmengonzalezlois identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT estherramirezmedina identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT belenalmoguera identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT antoniojsanchezlopez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT laurabindila identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT sigridhamann identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT norbertarnold identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT christophrocken identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT ignacioherasmurillo identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT davidsancho identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT gemamorenobueno identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT mariamcaffarel identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT manuelguzman identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT cristinasanchez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer AT eduardoperezgomez identificationoffattyacidamidehydrolaseasametastasissuppressorinbreastcancer |